Htg molecular diagnostics, inc (HTGM)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue:
Total revenue

2,225

4,799

5,404

5,796

3,202

7,728

4,706

4,910

4,158

-

3,723

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product and product-related services

-

-

-

-

-

-

-

-

-

-

-

1,458

1,371

3,449

506

577

600

1,182

973

648

727

810

532

75

370

Collaborative development services

-

-

-

-

-

-

-

-

-

-

-

302

-

-

407

1,318

265

33

37

51

62

100

107

74

214

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

91

234

386

230

184

241

Total revenue

-

-

-

-

-

-

-

-

-

-

-

1,760

1,371

1,457

913

1,895

865

1,215

1,010

790

1,024

1,297

870

334

826

Cost of revenue

-

-

-

-

-

-

-

-

-

-

1,088

1,236

1,295

1,234

1,125

932

843

796

809

834

894

1,199

747

615

642

Gross margin

-

-

-

-

-

-

-

-

-

-

2,634

523

75

223

-211

962

21

418

201

-44

129

98

122

-281

184

Operating expenses:
Cost of product and product-related services revenue

1,015

1,418

2,939

2,508

2,045

1,263

1,239

1,450

1,137

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

4,675

5,024

4,516

4,740

4,400

4,842

4,709

4,764

5,657

4,603

4,258

4,413

4,238

4,083

3,937

4,712

4,693

4,111

3,717

3,726

3,439

2,781

2,610

2,429

2,076

Research and development

1,926

2,671

2,570

3,253

2,074

3,688

3,561

2,758

2,589

3,632

3,478

1,618

1,267

1,384

1,910

2,611

1,994

1,650

1,309

953

688

702

649

865

857

Total operating expenses

7,617

9,114

10,025

10,502

8,521

9,793

9,511

8,974

9,384

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

7,736

6,032

5,505

5,468

5,847

7,324

6,687

5,761

5,026

4,679

4,127

3,483

3,260

3,294

2,934

Operating loss

-5,391

-4,314

-4,620

-4,706

-5,318

-2,065

-4,804

-4,063

-5,225

-1,682

-5,102

-5,508

-5,429

-5,244

-6,058

-6,361

-6,666

-5,343

-4,825

-4,724

-3,997

-3,385

-3,137

-3,576

-2,750

Other income (expense):
Loss from change in stock warrant valuation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

628

-388

-

0

56

-

Interest expense

225

242

241

238

233

251

234

233

182

258

300

350

398

445

490

538

392

385

378

476

479

414

161

56

74

Interest income

141

168

118

154

181

189

195

197

133

21

22

17

12

19

26

31

35

36

37

11

0

-

-

-

-

Other income

22

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of Growth Term Loan

-

-

-

-

-

0

0

0

-105

-

-

-

-

-

-

-

-

-

-

-705

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35

18

-

-

8

70

-

-5

-8

4

-2

Total other expense

-61

-74

-123

-84

-52

-62

-38

-35

-154

-237

-277

-332

-386

-422

-429

-489

-356

-346

-332

-1,728

-90

-

-169

-

-

Net loss before income taxes

-5,452

-4,389

-4,743

-4,790

-5,370

-

-4,843

-4,099

-

-1,920

-5,380

-5,840

-5,815

-5,667

-6,488

-6,850

-7,023

-5,689

-5,157

-6,452

-4,088

-4,138

-3,307

-3,684

-2,827

Provision for income taxes

5

-

-3

6

-

-

-

3

-

1

0

0

0

5

0

0

3

-

-

-

-

-

-

-

-

Net loss

-5,457

-4,389

-4,740

-4,797

-5,370

-2,127

-4,843

-4,102

-5,379

-1,921

-5,380

-5,840

-5,816

-5,673

-6,488

-6,851

-7,026

-5,699

-5,157

-6,452

-4,088

-4,138

-3,307

-3,684

-2,827

Accretion of stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

10

24

-125

19

186

22

Accretion of Series E warrant discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

40

87

-

-

-

51

Accretion of Series D and E redeemable convertible preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

367

798

-

-

-

-

Accretion of Series D and E redeemable convertible preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

837

828

740

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,699

-5,157

-6,870

-4,998

-4,932

-4,258

-4,784

-3,642

Net loss per share, basic and diluted

-0.08

0.00

-0.15

-0.17

-0.19

-0.07

-0.17

-0.14

-0.22

0.00

-0.46

-0.60

-0.73

-0.74

-0.92

-0.98

-1.02

12.45

-0.76

-1.73

-14.99

-43.47

-44.14

-49.62

-37.80

Shares used in computing net loss per share, basic and diluted

64,567

63,773

31,367

28,657

28,600

28,579

28,434

28,375

24,704

13,045

11,603

9,769

7,971

7,495

7,053

7,018

6,885

6,937

6,829

3,973

333

113

96

96

96

Product and Product-related Services
Total revenue

1,988

3,234

4,311

4,424

2,662

4,049

1,314

2,023

1,733

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaborative Development Services
Total revenue

237

1,565

1,093

1,371

540

3,678

3,391

2,887

2,425

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-